UroGen Pharma Ltd. - Ordinary Shares (URGN) News
Filter URGN News Items
URGN News Results
|Loading, please wait...|
URGN News Highlights
- URGN's 30 day story count now stands at 2.
- Over the past 2 days, the trend for URGN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest URGN News From Around the Web
Below are the latest news stories about UROGEN PHARMA LTD that investors may wish to consider to help them evaluate URGN as an investment opportunity.
Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer
PRINCETON, N.J., January 11, 2023--JELMYTO Real-World Data Published in Journal of Urologic Oncology
Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow...
UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
PRINCETON, N.J., December 19, 2022--UroGen Completes Enrollment of its Phase 3 study for UGN-102 in development for treatment of LG-IR-NMIBC
With 57% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big guns
A look at the shareholders of UroGen Pharma Ltd. ( NASDAQ:URGN ) can tell us which group is most powerful. The group...
PRINCETON, N.J., December 09, 2022--UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 12 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercial launch of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen’s first approved product, and the c
UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
SAN DIEGO, December 02, 2022--UroGen Announces new Data from OPTIMA II at SUO 2022
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer
SAN DIEGO, December 02, 2022--UroGen Announces New Data from the OLYMPUS Trial at SUO 2022
PRINCETON, N.J., November 21, 2022--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a virtual fireside chat at the upcoming Evercore ISI 5th Annual HealthCONx Conference on November 29, 2022 at 3:55 PM ET.
Today is shaping up negative for UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders, with the analysts delivering a...
UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma
PRINCETON, N.J., November 14, 2022--UroGen Highlights New Real-World Safety Data from a Retrospective Study Published in The British Journal of Urology International